HomeAI · summaries
Storia in 2 fonti
FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote
FDA grants accelerated approval to AstraZeneca's Etcamah for ESR1-mutant breast cancer despite an adcomm rejection; Jefferies sees $5B+ peak sales.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote
FDA grants accelerated approval to AstraZeneca's Etcamah for ESR1-mutant breast cancer despite an adcomm rejection; Jefferies sees $5B+ peak sales.
- ·
medpagetoday.com
Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors
Oral SERD camizestrant lands indication for use in novel first-line treatment strategy